Human epidermal growth factor receptor 2 as amolecular biomarker formetastatic colorectal cancer

JAMA Oncology

Volumn 4, Issue 1, 2018, Pages 19-20

  Sartore Bianchi, Andrea ^a   Marsoni, Silvia ^a,b   Siena, Salvatore ^a,c  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b CANDIOLO CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BIOLOGICAL MARKER; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN; LAPATINIB; PANITUMUMAB; PEMBROLIZUMAB; PERTUZUMAB; TRASTUZUMAB; ERBB2 PROTEIN, HUMAN; TUMOR MARKER;

BRAF GENE; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER STAGING; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC SCREENING; HER2 GENE; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KRAS GENE; METASTATIC COLORECTAL CANCER; MISMATCH REPAIR; NOTE; ONCOGENE RAS; PREDICTIVE VALUE; PROTEIN EXPRESSION; TREATMENT RESPONSE; CLINICAL TRIAL (TOPIC); COLORECTAL TUMOR; GENETICS; METASTASIS; MOLECULAR DIAGNOSIS; PATHOLOGY; PHYSIOLOGY; PRACTICE GUIDELINE; PROCEDURES; PROGNOSIS; STANDARDS;

BIOMARKERS, TUMOR; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; GENE AMPLIFICATION; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASM METASTASIS; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RECEPTOR, ERBB-2;

EID: 85041628543     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2017.3323     Document Type: Note

References (8)

1. Sepulveda AR, Hamilton SR, Allegra CJ, et al. molecular biomarkers for the evaluation of colorectal cancer: Guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. J Clin Oncol. 2017;35(13):1453-1486.
2. Sartore-Bianchi A, Trusolino L, Martino C, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positivemetastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17(6):738-746.
3. Siena S, Sartore-Bianchi A, Trusolino L, et al. Final results of the HERACLES trial in HER2 amplified colorectal cancer. Anti-HER2 treatment in HER2+ mCRC. Oral presentation at the AACR Annual Meeting 2017;Washington, DC. Abstract CT005.
4. Hurwitz H, Raghav KPS, Burris HA, et al. Pertuzumab + trastuzumab for HER2-amplified/ overexpressed metastatic colorectal cancer (mCRC): Interim data from MyPathway. J Clin Oncol. 2017;35(suppl 4):676-676.
5. Valtorta E, Martino C, Sartore-Bianchi A, et al. Assessment of a HER2 scoring system for colorectal cancer: Results from a validation study. Mod Pathol. 2015;28(11):1481-1491.
6. Richman SD, Southward K, Chambers P, et al. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: Analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLOcolorectal cancer trials. J Pathol. 2016;238(4):562-570.
7. Bertotti A, Migliardi G, Galimi F, et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 2011;1(6):508-523.
8. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409-413.